SME · BSE SMEListed
Goldline Pharmaceutical Limited IPO: dates, price band, lot size, objects of the issue
Get analyst updates on this IPO
Analyst updates come by email.What changed since listing, from SEBI-registered research analysts.
By continuing you agree to the Terms and Privacy policy
Key facts
- Issue size at the upper band
- ₹11.61 crore
- Listing date
- Tue 19 May 2026
- BSE daily price file for Tue 19 May 2026
Timeline (IST)
- OpensTue 12 May 2026, 10:00 am IST confirmedProspectus dated Thu 14 May 2026, page 71
- ClosesThu 14 May 2026 confirmedProspectus dated Thu 14 May 2026, page 71
- UPI mandate cut-offNot stated in the prospectus Prospectus dated Thu 14 May 2026
- AllotmentFri 15 May 2026 by T+3 schedule
- Refund and unblockMon 18 May 2026 by T+3 schedule
- Shares to dematMon 18 May 2026 by T+3 schedule
- ListingTue 19 May 2026 confirmedBSE daily price file for Tue 19 May 2026
Objects of the issue
| Object | Amount |
|---|---|
| Repayment of all or a portion of certain outstanding borrowings availed by our company | ₹8.35 crore |
| General corporate purposes | ₹1.71 crore |
| Total | ₹10.06 crore |
Prospectus dated Thu 14 May 2026, page 89
Company and promoters
As described in the prospectus
We are engaged in the business of marketing pharmaceutical products under the brand name “Goldline.”
Prospectus dated Thu 14 May 2026, page 127
Promoters
- 2 individual promoters
Prospectus dated Thu 14 May 2026, page 196
Shareholding
| Holding | Before the issue | After the issue |
|---|---|---|
| Promoters and promoter group | 79.70% | Not stated in the prospectus |
| Public | 20.30% | Not stated in the prospectus |
Prospectus dated Thu 14 May 2026, page 80
Financials (restated)
| Item | Nine months ended December 31, 2025 | March 31, 2025 | March 31, 2024 | March 31, 2023 |
|---|---|---|---|---|
| Revenue from operations | ₹21.41 crore | ₹28.06 crore | ₹23.57 crore | ₹19.85 crore |
| Profit after tax | ₹2.22 crore | ₹2.83 crore | ₹1.80 crore | ₹25.66 lakh |
| Net worth | ₹12.36 crore | ₹10.35 crore | ₹7.86 crore | ₹5.89 crore |
| Total borrowings | Not stated in the prospectus | Not stated in the prospectus | Not stated in the prospectus | Not stated in the prospectus |
Prospectus dated Thu 14 May 2026, page 60
SME issue facts
- The Issue comprises a Fresh Issue of Equity shares. (Prospectus dated Thu 14 May 2026, page 280)
- that the minimum application size shall be two lots per application: (Prospectus dated Thu 14 May 2026, page 281)
- will be only in electronic form in multiples of 3000 Equity Shares, subject to a minimum Allotment of 6000 Equity (Prospectus dated Thu 14 May 2026, page 281)
- of allottees in this Issue shall be 200 shareholders. (Prospectus dated Thu 14 May 2026, page 281)
Peer comparison (as in the Prospectus)
| Name of the Company | Face value (₹) | Revenue from operations (₹ in Lakhs)(1) | Basic EPS (₹) | Diluted EPS (₹) | P/E (based on Diluted EPS) | Return on net worth (%) | NAV per Equity Share (₹) |
|---|---|---|---|---|---|---|---|
| Goldline Pharmaceutical Limited | 10 | 2,805.57 | 4.10 | 4.10 | 10.49 | 27.37 | 12.38 |
| Mono Pharmacare Limited | 10 | 16,834.49 | 1.75 | 1.75 | 7.57 | 9.90 | 17.66 |
| Chandra Bhagat Pharma Limited | 10 | 8,671.61 | 1.14 | 1.14 | 28.94 | 2.86 | 39.72 |
Reproduced from the Prospectus dated Thu 14 May 2026, page 97; InsightPier adds no figures
Risk factors
78 total- The company depends fully on outside contract manufacturers to make its products (offer document page 20)
- The company has filed forms with the Registrar of Companies late in the past and paid late fees (offer document page 23)
- The business depends on economic conditions in India (offer document page 55)
- Foreign investors face restrictions under Indian law (offer document page 55)
- Wars and conflicts abroad may affect the global economy and the business (offer document page 56)
All 78 risk factors, pages 19 to 56
Offer document
Allotment and bids
Registrar to the issue: Bigshare Services Private Limited.
Allotment status was expected on the registrar's site from Fri 15 May 2026 and is not yet confirmed. Pick "Goldline Pharmaceutical Limited" from the issue list there.
Subscription (final)
| Category | Shares offered | Shares bid for | Times subscribed |
|---|---|---|---|
| Overall | – | – | 840.74× |
ipowatch.in, as of Tue 17 Nov 2026